CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation
CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia
Sponsor: Varian, a Siemens Healthineers Company
This NA trial investigates Tachycardia, Ventricular and is currently completed. Varian, a Siemens Healthineers Company leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Oct 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Mar 2022 — Oct 2023 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting NA
▶ Show 8 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Recruiting NA
-
Jun 2018 — Feb 2020 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2018 — May 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jan 2018 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Varian, a Siemens Healthineers Company
For direct contact, visit the study record on ClinicalTrials.gov .